Efferon therapy

22/05/2026

Efferon at the Pharma Partnering Summit, Basel

Over the past few days, Efferon's leadership joined business development executives from leading European pharma and biotech companies in Basel. The discussions focused on what makes partnerships successful in practice: trust, transparency and a shared commitment to patients health.

When standard therapy alone is not enough, adjunctive treatments can play an important role in improving patient outcomes. In his presentation, Efferon CEO Dima Romashin discussed the potential of hemoadsorption in oncology, rare diseases and autoimmune conditions, where controlling dysregulated inflammation may help improve the overall treatment journey for patients.

Thank you to Dimitri F. Dimitriou, FRSM, FRSC, FRSB and the DyoDelta Biosciences Ltd. team for organizing a meeting, and to BeGlobe for connecting Efferon with this community.

20/05/2026

Efferon at the Pharma Partnering Summit Europe 2026!

Join us in on 20–21 May 2026, to learn more about Efferon’s innovative next-generation hemoadsorption technologies and discuss new opportunities for collaboration in critical care and beyond.

We are also pleased to invite attendees to Dima Romashin’s presentation, scheduled for Day 2, 21 May 2026, from 12:50–13:10, where he will share insights into Efferon’s technology and its potential impact on patient care. As continues to affect nearly 50 million people and claim millions lives each year worldwide, innovative treatment approaches remain critical priorities for healthcare systems globally.

See you there!

18/05/2026

Congratulations to Vedran Premužić and the entire organizing committee for a great 4th International Conference on Extracorporeal Organ Support in and an excellent opportunity to bring together the intensive care and critical care community.

Together with MEDICON and BERTOSSI, we were pleased to discuss multimodal hemoadsorption and the evolving role of Efferon in sepsis and septic shock management.

was among the key topics of discussion. A special moment of the event was Ivan Bessonov's lecture on the LASSO NEO multicenter clinical trial results. Based on these findings, the world's first multimodal hemoadsorption device for pediatric use, Efferon NEO, was approved for the treatment of neonatal and pediatric sepsis and septic shock. Children treated with NEO demonstrated faster shock resolution, reduced organ dysfunction, decreased need for vasopressors and mechanical ventilation, and meaningful reductions in inflammatory markers, cytokines, and endotoxin.

Thank you to everyone who joined the discussions. See you at the next event!

Highlights from Efferon’s participation at the Extracorporeal Organ Support Conference in Zagreb.Together with our partners MEDICON and BERTOSSI, we presente...

14/05/2026

Looking at this photo, you might think it’s just the beautiful cliffs of England. In reality, it’s probably Dima Romashin scouting the next market for Efferon expansion.

Today, we celebrate the birthday of our CEO and Co-Founder, Dmitrii Romashin, one of the founding fathers of Efferon and a person who has never been very good at thinking “small.”

Many years ago, Dima saw a bold scientific idea and decided it deserved more than staying inside a laboratory or presentation slide. Together with his co-founder, Ivan Bessonov, he helped build what Efferon is today: a team of people who believed that “impossible” usually just means “give us some more time.”

Happy Birthday, Dima, and thank you for building, believing, and inspiring.

The Efferon Team 🎉

12/05/2026

When Standard Therapy Fails: Hemoadsorption as a Lifeline
When you've done everything right but your patient isn't responding to standard therapy, what's next?
A critical care physician professor Zsolt Molnar shares a crucial insight: if hyperinflammation is driving your patient's critical condition and they have a fighting chance, hemoadsorption could be the additional support that makes the difference between life and death.

💡 Follow Efferon for more evidence-based insights on hemoadsorption and critical care innovations.

12/05/2026

Efferon not only develops technologies that help save lives, but also supports young talents and enthusiasts building something meaningful for the future.

The Sepsis Atlas Hackathon in Aachen has concluded. Over two days, teams worked on building AI-powered tools to extract and structure data from clinical sepsis research papers. The goal was to create applications that could analyze large volumes of unstructured literature and make it queryable and usable for R&D purposes.

Selecting winners was difficult, all teams demonstrated solid technical ex*****on.

🎉 Congratulations to the winners for their impressive work and good luck in their future projects. Thanks to all participants, and to SchubKI GmbH, Nadezhda Styazhkina, Alena Salakhova and BEST Aachen for organisation.

08/05/2026

The Economics of Saving Lives: Hemoadsorption Impact
Can hemoadsorption actually save healthcare costs? A critical care physician professor Zsolt Molnar breaks down the economics.

The cost-effectiveness is indirect but significant:
✅ Reduced need for organ support
✅ Faster hemodynamic improvement
✅ Lower vasopressor requirements
✅ Shorter ventilation time
✅ Earlier ICU discharge

The bottom line: every day saved in ICU has substantial economic impact.

Want to learn more about evidence-based hemoadsorption strategies? Follow Efferon International for clinical and economic insights!

08/05/2026

What a wonderful first day at the Extracorporeal Organ Support conference in Zagreb!

Our co-founder Ivan Bessonov, creator of Efferon's core technology, presented results from the multicenter LASSO NEO study, demonstrating 's efficacy in reducing mediators and improving clinical outcomes in critically ill young patients with sepsis.

Based on these results, Efferon NEO has received CE MDR certification, becoming the world's first multimodal device specifically approved for neonatal and pediatric sepsis and septic shock.

Special thanks to our partners MEDICON and BERTOSSI for organizing the booth and promoting Efferon technology across the region. See you at other events!

06/05/2026

First Hemoadsorption Device for Newborns & Children | A New Era in Pediatric Critical Care
For the first time in history, hemoadsorption is now possible for newborns and children.

We are proud to introduce Efferon NEO, the world's first hemoadsorption device, specifically designed for neonatal and pediatric patients. Until now, critically ill infants had no access to this life-saving therapy. We changed that.

30/04/2026

Hemoadsorption & Endothelium: The Next Breakthrough?

We can remove biomarkers, but does it actually improve patient outcomes?

Discover the hypothesis linking hemoadsorption to endothelial protection, vascular tone, and organ function. This could shape the next generation of ICU research.

🔔 Follow for more high-impact medical insights!

28/04/2026

Biomarkers or Clinical Signs? ICU Expert Explains

In critical care, timing is everything. So how do doctors decide when to start Efferon hemoadsorption therapy?

In this short, an ICU expert professor Zsolt Molnar explains why clinical condition and hemodynamic instability matter more than biomarkers alone, and when it's time to act.

👉 Watch till the end and subscribe for more real ICU insights and medical education!